[go: up one dir, main page]

MX2019007968A - Compuestos medicinales y suplementos nutricionales. - Google Patents

Compuestos medicinales y suplementos nutricionales.

Info

Publication number
MX2019007968A
MX2019007968A MX2019007968A MX2019007968A MX2019007968A MX 2019007968 A MX2019007968 A MX 2019007968A MX 2019007968 A MX2019007968 A MX 2019007968A MX 2019007968 A MX2019007968 A MX 2019007968A MX 2019007968 A MX2019007968 A MX 2019007968A
Authority
MX
Mexico
Prior art keywords
nutritional supplements
medicinal compounds
carriers
various
carrier
Prior art date
Application number
MX2019007968A
Other languages
English (en)
Inventor
Leone-Bay Andrea
WESNER Gregory
Original Assignee
Receptor Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62790943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019007968(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Receptor Holdings Inc filed Critical Receptor Holdings Inc
Publication of MX2019007968A publication Critical patent/MX2019007968A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen compuestos medicinales o suplementos nutricionales de cannabinoide sintético en diversas combinaciones de portador. Los portadores pueden incluir aminoácidos grasos N-acilados, potenciadores de penetración y/o diversos otros portadores favorables. Las combinaciones de portador/composición de cannabinoide sintético pueden crear beneficios de administración.
MX2019007968A 2017-01-03 2018-01-03 Compuestos medicinales y suplementos nutricionales. MX2019007968A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762441908P 2017-01-03 2017-01-03
PCT/US2018/012261 WO2018129097A1 (en) 2017-01-03 2018-01-03 Medicinal compounds and nutritional supplements

Publications (1)

Publication Number Publication Date
MX2019007968A true MX2019007968A (es) 2019-12-05

Family

ID=62790943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007968A MX2019007968A (es) 2017-01-03 2018-01-03 Compuestos medicinales y suplementos nutricionales.

Country Status (14)

Country Link
US (2) US20190336472A1 (es)
EP (1) EP3565539A4 (es)
JP (3) JP7281815B2 (es)
KR (1) KR20190103302A (es)
CN (1) CN110121337A (es)
AU (2) AU2018206564B2 (es)
BR (1) BR112019013743A2 (es)
CA (1) CA3049226A1 (es)
CL (1) CL2019001832A1 (es)
CO (1) CO2019008176A2 (es)
EA (1) EA201991641A1 (es)
IL (1) IL267831A (es)
MX (1) MX2019007968A (es)
WO (1) WO2018129097A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180781B2 (en) * 2016-08-21 2021-11-23 Insectergy, Llc Biosynthetic cannabinoid production methods
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
EA201991641A1 (ru) * 2017-01-03 2020-03-10 Ресептор Холдингз, Инк. Лекарственные соединения и пищевые добавки
US20210052544A1 (en) * 2018-01-29 2021-02-25 Solantech Inc. Methods of treating and/or preventing bedsores using nabilone
MX2021004138A (es) * 2018-10-10 2021-08-05 Tilray Inc Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.
WO2020106767A1 (en) * 2018-11-19 2020-05-28 Receptor Holdings, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
US11622956B1 (en) 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
EP3946262B1 (en) 2019-08-30 2024-07-31 Evie Sa Loaded granules, their process of production and their uses
CA3159949A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Agents for oral composition
US12171872B2 (en) 2019-12-09 2024-12-24 Nicoventures Trading Limited Oral compositions and methods of manufacture
CN113040337B (zh) * 2021-04-22 2022-12-09 四川大学 一种熏肉制品及其制备方法
WO2024253228A1 (ko) * 2023-06-09 2024-12-12 주식회사 메타파인즈 악액질 및 근손실의 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1017366A4 (en) * 1996-09-01 2006-03-22 Pharmos Corp SOLID COPARCIPITATES FOR IMPROVED BIOVERABILITY OF LIPOPHILIC SUBSTANCES
JP5196701B2 (ja) * 2001-11-29 2013-05-15 エミスフィアー テクノロジーズ インコーポレイテッド クロモリンナトリウムの経口投与用製剤
US9308175B2 (en) * 2006-09-15 2016-04-12 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
TR201815752T4 (tr) * 2010-11-25 2018-11-21 Aop Orphan Pharmaceuticals Ag Nabilon ve rastomal metilen beta siklodekstrin içeren hızlı parçalanan bileşimler.
EP2747563A4 (en) * 2011-08-26 2015-06-24 Aegis Therapeutics Llc COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
CN109069475B (zh) * 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
EA201991641A1 (ru) 2017-01-03 2020-03-10 Ресептор Холдингз, Инк. Лекарственные соединения и пищевые добавки

Also Published As

Publication number Publication date
US20190336472A1 (en) 2019-11-07
AU2024201078A1 (en) 2024-03-07
IL267831A (en) 2019-09-26
AU2018206564A1 (en) 2019-08-15
CO2019008176A2 (es) 2019-08-20
KR20190103302A (ko) 2019-09-04
JP2023071697A (ja) 2023-05-23
EA201991641A1 (ru) 2020-03-10
CN110121337A (zh) 2019-08-13
EP3565539A1 (en) 2019-11-13
CL2019001832A1 (es) 2020-01-31
US20230293479A1 (en) 2023-09-21
CA3049226A1 (en) 2018-07-12
BR112019013743A2 (pt) 2020-01-21
JP7466238B2 (ja) 2024-04-12
JP2020503357A (ja) 2020-01-30
WO2018129097A1 (en) 2018-07-12
JP7281815B2 (ja) 2023-05-26
JP2024075724A (ja) 2024-06-04
AU2018206564B2 (en) 2023-12-07
EP3565539A4 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
MX2019007968A (es) Compuestos medicinales y suplementos nutricionales.
CO2018011299A2 (es) Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción
CO2019005565A2 (es) Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción
CO2020005349A2 (es) Composiciones de hierbas con mejor biodisponibilidad
CL2020000909A1 (es) Formulaciones cannabinoides sintéticas y basadas en plantas de rapido inicio y de acción prolongada.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CY1123853T1 (el) Ρυθμιστες nrf2
CO2019009258A2 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
CL2017003404A1 (es) Compuestos antibacterianos
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
BR112018012707A2 (pt) inibidores da interação de menin-mll
CL2016001345A1 (es) Producto farmacéutico que comprende a un inhibidor de la interacción mdm2-p53 y b citarabina y uso para el tratamiento del cáncer.
MX388858B (es) Reducción de la viscosidad de formulaciones farmacéuticas
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
ECSP15009928A (es) Producto de pienso y/o ingrediente de pienso
EA201791716A1 (ru) Фармацевтический состав
MX2018006820A (es) Complejos de aminoacidos metalicos para la acumulacion bacteriana.
MX2019013251A (es) Una composicion nutricional para usarse para mejorar la atencion y/o reducir la impulsividad.
EA201891256A1 (ru) Индивидуальная активация в подгруппе источников
MX2019005340A (es) Composiciones y metodos de alimento para mascotas.
AR105728A1 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
CL2020003389A1 (es) Composición cosmética estable aclaradora de la piel